NYSE - Nasdaq Real Time Price USD
Teva Pharmaceutical Industries Limited (TEVA)
As of 12:25 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 11 | 11 |
| Avg. Estimate | 0.66 | 0.72 | 2.45 | 2.77 |
| Low Estimate | 0.63 | 0.65 | 2.37 | 2.59 |
| High Estimate | 0.68 | 0.77 | 2.51 | 3.1 |
| Year Ago EPS | 0.6 | 1 | 2.56 | 2.45 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 10 | 10 |
| Avg. Estimate | 4.12B | 4.16B | 16.26B | 16.88B |
| Low Estimate | 4.02B | 4.09B | 16.15B | 16.29B |
| High Estimate | 4.19B | 4.22B | 16.39B | 17.64B |
| Year Ago Sales | 3.85B | 4.46B | 15.85B | 16.26B |
| Sales Growth (year/est) | 7.00% | -6.70% | 2.60% | 3.80% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | 0.61 | 0.77 | 0.51 | 0.55 |
| EPS Actual | 0.6 | 1 | 0.48 | 0.61 |
| Difference | -0.01 | 0.23 | -0.03 | 0.06 |
| Surprise % | -1.60% | 29.90% | -5.90% | 10.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.66 | 0.72 | 2.45 | 2.77 |
| 7 Days Ago | 0.66 | 0.71 | 2.44 | 2.76 |
| 30 Days Ago | 0.66 | 0.71 | 2.44 | 2.77 |
| 60 Days Ago | 0.66 | 0.71 | 2.44 | 2.77 |
| 90 Days Ago | 0.65 | 0.78 | 2.34 | 2.74 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 2 | 2 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | TEVA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 10.00% | -- | -- | 3.10% |
| Next Qtr. | -28.00% | -- | -- | 8.00% |
| Current Year | -4.30% | -- | -- | 2.30% |
| Next Year | 13.10% | -- | -- | 13.20% |
| Next 5 Years (per annum) | 1.60% | -- | -- | 11.85% |
| Past 5 Years (per annum) | -0.30% | -- | -- | -- |
Upgrades & Downgrades
| Maintains | JP Morgan: Neutral to Neutral | 10/21/2024 |
| Maintains | UBS: Buy to Buy | 9/3/2024 |
| Maintains | Barclays: Overweight to Overweight | 8/1/2024 |
| Maintains | UBS: Buy to Buy | 7/11/2024 |
| Maintains | Jefferies: Buy to Buy | 6/27/2024 |
| Maintains | Barclays: Overweight to Overweight | 6/5/2024 |
Related Tickers
VTRS Viatris Inc.
11.69
+1.03%
BHC Bausch Health Companies Inc.
8.11
-0.73%
TLRY Tilray Brands, Inc.
1.6909
+7.02%
HLN Haleon plc
9.89
-0.95%
CGC Canopy Growth Corporation
4.9500
+14.06%
PRGO Perrigo Company plc
25.79
-0.25%
ZTS Zoetis Inc.
188.11
-0.71%
ELAN Elanco Animal Health Incorporated
12.58
-0.36%
AKAN Akanda Corp.
1.0400
-2.80%
AMRX Amneal Pharmaceuticals, Inc.
8.50
+0.30%